Appetite Hormones in Binge Eating Disorder

Status Completed

Clinical Trial Summary

This study investigates the hormones that the body produces in response to food intake and in response to stress, and the way that stress influences food intake. In particular, it compares the hormone levels and food intake of people with and without binge eating disorder. In order to find out how these appetite- and stress-related hormones are linked to brain activity, the study also includes an fMRI scan, a non-invasive procedure that looks at which regions of the brain are most active during a food-related scenario.

Clinical Trial Description

The objectives are to study appetite-related hormones regulating food intake under normal conditions and following a stressor in the morning and evening (when most binge episodes occur), to help reveal biological mechanisms in BED. We plan to enroll: 32 obese Ss with BED (16m, 16f), 32 obese Ss without BED (16m, 16f) and 32 normal-weight Ss without BED (16m, 16f). Height, weight, waist circumference, and body fat will be assessed during a first appointment. On two different days separated by at least a week, Ss will ingest a fixed liquid meal once in the morning and once in the evening. Appetite ratings and collections of blood and saliva to measure hormones will continue for 2 hours after the fixed meal. This will be followed on each day by a laboratory stress protocol (Socially Evaluated Cold Pressor Test; SECPT), and then consumption of an ad libitum meal 30 minutes later. On one day during the protocol, the participant will collect saliva using a swab immediately after waking and again at 08.00. In order to capture more naturalistic eating episodes, all Ss will additionally record food intake, rate appetite, and measure salivary cortisol before and after one evening meal, and one after-dinner snack (or after-dinner binge for BED Ss). On two additional days, we will use fMRI to assess brain activation in response to high-palatability food (HPF) relative to low-palatability food (LPF) or non-food (NF) visual cues following the SECPT and a control condition using warm water. On each day, following the fMRI scan, an ad libitum meal will be consumed. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01552759
Study type	Interventional
Source	New York Obesity and Nutrition Research Center
Contact
Status	Completed
Phase	N/A
Start date	May 2007
Completion date	January 2012

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02978742` - Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder	N/A
Recruiting	`NCT02659488` - Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects	Phase 2
Completed	`NCT02659475` - Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)	Phase 2
Completed	`NCT00601653` - Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder	N/A
Completed	`NCT02834299` - Dialectical Behavior Therapy Guided Self-Help for Binge Eating Disorder	N/A
Completed	`NCT02553824` - FDA Approved Medication to Reduce Binge Eating and/or Purging	Phase 1
Completed	`NCT02564588` - Dasotraline Binge Eating Disorder Study	Phase 2/Phase 3
Completed	`NCT00307190` - Hormone Release and Stomach Disturbances in People With Binge Eating Disorder	N/A
Completed	`NCT01718509` - SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder	Phase 3
Completed	`NCT01718483` - SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder	Phase 3
Completed	`NCT02503098` - Optimizing a Smartphone Application for Individuals With Eating Disorders	N/A
Active, not recruiting	`NCT01837953` - Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial	N/A
Completed	`NCT01010789` - Armodafinil in Binge Eating Disorder (BED)	Phase 3
Completed	`NCT01098435` - ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder	Phase 2
Completed	`NCT00330655` - An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder	Phase 4
Completed	`NCT01291173` - Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder	Phase 2
Completed	`NCT03107026` - A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder	Phase 3
Completed	`NCT02079935` - Treatment of Eating Disorders by Physical Activity and Nutrition Counseling	N/A
Completed	`NCT00277641` - Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity	Phase 3
Completed	`NCT00032760` - Meditation-Based Treatment for Binge Eating Disorder	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.